ArticleNano letters2025
Deep Learning-Assisted SERS for Therapeutic Drug Monitoring of Clozapine in Serum on Plasmonic Metasurfaces.
Article in Nano letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Sulfate-Directed Silver Dendrites with Enhanced Stability for Ultrasensitive SERS-Based Therapeutic Drug Monitoring.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- SERS-powered precision: revolutionizing therapeutic drug monitoring with nanoscale sensitivity.Mikrochimica acta · 2025Review
- Clozapine Drug-Drug Interactions and Individualized Dosing in Bipolar Disorder: A Model-Informed Precision Dosing Approach.Drug design, development and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Clozapine is widely regarded as one of the most effective therapeutics for treatment-resistant schizophrenia. Despite its proven efficacy, the therapeutic use of clozapine is complicated by its narrow therapeutic index, which necessitates rapid and precise therapeutic drug monitoring (TDM) to optimize patient outcomes and minimize adverse effects. However, conventional techniques, such as high-performance liquid chromatography, are limited by their high costs, complex instrumentation, and long turnaround times. Herein, we propose a novel approach that integrates artificial neural networks (ANNs) with surface-enhanced Raman spectroscopy (SERS) on a plasmonic metasurface for rapid TDM of clozapine and its two primary metabolites, norclozapine and clozapine-N-oxide, in human serum. The ANN-SERS strategy enables accurate classification and robust concentration prediction of the three analytes. We envision that the integrated ANN-SERS framework could deliver a scalable biomedical diagnostic and therapeutic tool for studying a wide variety of chemical and biological molecules in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.